๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Laparoscopic splenectomies for idiopathic thrombocytopenic purpura: Experience of sixty cases

โœ Scribed by Szold, Amir; Schwartz, Joseph; Abu-Abeid, Subhi; Bulvik, Shlomo; Eldor, Amiram


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
32 KB
Volume
63
Category
Article
ISSN
0361-8609

No coin nor oath required. For personal study only.

โœฆ Synopsis


We performed a laparoscopic splenectomy (LS) in 60 patients (age 9-83, 45 females) with idiopathic thrombocytopenic purpura (ITP) who did not achieve sustained remission on steroid therapy. Using a modified procedure, the mean duration of LS was 78 min (range 25-240 min) and surgery was associated with only 5% major and 5% minor complications. Ten patients had a platelet count less than 50 ร— 10 9 /l during surgery despite the administration of immune globulin (0.4 g/kg ร— 3-5 days) or pulsed oral dexamethasone (40 mg/day ร— 4 days). Three patients were refractory to these therapies and underwent LS with a platelet count less than 5 ร— 10 9 /l. Bleeding complications during or after surgery were rare (5%). Accessory spleens were removed in eight patients. Convalescence was rapid and the mean hospital stay was 2.3 days (range 1-7 days). The patients were followed for a mean of 16 months (range 1-36 months), and 49 patients (84%) are in complete remission. Seven patients (12.5%) relapsed despite an initial good response in 6 of them. Two patients underwent laparoscopic removal of accessory spleens with excellent response. We conclude that LS for ITP is safe and effective and associated with low morbidity and fast recovery. Thus, LS may be considered earlier in the course of ITP.


๐Ÿ“œ SIMILAR VOLUMES


Rituximab for the treatment of refractor
โœ Lydia Koulova; Doru Alexandrescu; Janice P. Dutcher; Kevin P. O'Boyle; Saji Eape ๐Ÿ“‚ Article ๐Ÿ“… 2004 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB ๐Ÿ‘ 2 views

Three patients (one with idiopathic thrombocytopenic purpura [ITP] and two with thrombotic thrombocytopenic purpura [TTP]) were treated with rituximab (anti-CD20 chimeric antibody) at a dose of 325 mg/m 2 administered weekly after they failed standard therapies. The patient with ITP who did not resp